Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
Andrew Blauvelt, Emma Guttman‐Yassky, Amy S. Paller, et al.
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 3, pp. 365-383
Open Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 48
Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human
Y Yamamura, Chisa Nakashima, Atsushi Otsuka
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 13
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study
Amy S. Paller, Elaine C. Siegfried, Eric L. Simpson, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 4, pp. 655-668
Open Access | Times Cited: 13
A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis
Elaine C. Siegfried, Lara Wine Lee, Jonathan M. Spergel, et al.
Pediatric Dermatology (2024) Vol. 41, Iss. 2, pp. 204-209
Open Access | Times Cited: 12
Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study
Mozhgan Hosseini-Ashrafi, Tim H Clayton, Michelle Herring, et al.
Clinical and Experimental Dermatology (2024) Vol. 49, Iss. 6, pp. 578-583
Open Access | Times Cited: 9
Interventions for anxiety and depression in patients with atopic dermatitis: a systematic review and meta-analysis
Stella Hartono, Sheena Chatrath, Ozge Nur Aktaş, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Emerging treatments for dermatologic diseases in infants, children, and adolescents: a systematic review of clinical trials on biologics and small molecule inhibitors
Alireza Jafarzadeh, Elham Behrangi, Mina Khosravi, et al.
Inflammopharmacology (2025) Vol. 33, Iss. 4, pp. 1617-1672
Closed Access | Times Cited: 1
Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations
Sneha Butala, Leslie Castelo‐Soccio, Rishi Seshadri, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 5, pp. 1361-1373
Open Access | Times Cited: 21
A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children
Mingyue Wang, Xing‐Hua Gao, Li Zhang
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 941-951
Open Access | Times Cited: 7
A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis
Katarzyna Waligóra-Dziwak, Aleksandra Dańczak‐Pazdrowska, Dorota Jenerowicz
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4001-4001
Open Access | Times Cited: 6
Dupilumab in the treatment of genodermatosis: A systematic review
Po‐Chien Wu, Ying‐Xiu Dai, Chia‐Lun Li, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2023) Vol. 21, Iss. 1, pp. 7-17
Closed Access | Times Cited: 15
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis
Michael J. Cork, Diamant Thaçi, Lawrence F. Eichenfield, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 11, pp. 2697-2719
Open Access | Times Cited: 15
Biologics in the management of childhood atopic dermatitis
Sneha Butala, Amy S. Paller
Journal of Allergy and Clinical Immunology (2023) Vol. 151, Iss. 3, pp. 681-685
Closed Access | Times Cited: 12
A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years
Cataldo Patruno, Gabriella Fabbrocini, Giuseppe Lauletta, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 12
Long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a prospective real-world cohort study in China
Yuyi Wang, Ruiling Jia, Hu Qin, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Modern Possibilities of Usage Dupilumab in Children
Anna A. Kosova, Anastasiya V. Fayans, Aishan Е. Ibaduiiaeva, et al.
Педиатрическая фармакология (2025) Vol. 21, Iss. 6, pp. 520-533
Open Access
Real‐life retrospective multicentre study to describe the use of dupilumab in paediatric patients with atopic dermatitis in Spain: Patient profile, effectiveness and safety
Eulàlia Baselga Torres, Marta Ivars, Carolina Prat, et al.
JEADV Clinical Practice (2025)
Open Access
Increasing dosing intervals for biologics in atopic dermatitis‐why, who, when and how?
M. E. Jacobson, Celeste M. Boesjes, Marjolein de Bruin‐Weller, et al.
Journal of the European Academy of Dermatology and Venereology (2025)
Closed Access
Efficacy and Safety of Dupilumab Across Different Th2-Type-Mediated Diseases: A Real-Life Preliminary Experience
Ciro Romano, Domenico Cozzolino, Maria Elena Corona, et al.
Biologics (2025) Vol. 5, Iss. 1, pp. 3-3
Open Access
Efficacy and Safety of Omalizumab and Dupilumab in Pediatric Patients with Skin Diseases: An Observational Study
Francesca Galletta, L Rizzuti, Stefano Passanisi, et al.
Journal of Personalized Medicine (2025) Vol. 15, Iss. 2, pp. 64-64
Open Access
Safety of Dupilumab Therapy for Atopic Dermatitis during Pregnancy: A Systematic Review and Meta-analysis
Verónica Sánchez‐García, E. De Miguel, José Manuel Ramos, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv41307-adv41307
Open Access
Just scratching the surface: A review of pediatric skin allergies
Mary Grace Baker, Lara S. Ford, Dianne E. Campbell, et al.
Pediatric Allergy and Immunology (2025) Vol. 36, Iss. 2
Closed Access
Tissue‐Resident Th2 Cells in Type 2 Immunity and Allergic Diseases
Jenny M. Mannion, Rod A. Rahimi
Immunological Reviews (2025) Vol. 330, Iss. 1
Closed Access
Comparative efficacy and safety of dupilumab versus newly approved biologics and JAKi in pediatric atopic dermatitis: A systematic review and network meta-analysis
Qiwei Liao, Hong Pan, Yixin Guo, et al.
PLoS ONE (2025) Vol. 20, Iss. 2, pp. e0319400-e0319400
Open Access
Correspondence on “Efficacy, Safety, and Early Relapse after Cessation of Upadacitinib Versus Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China”
Xiaojun Shi, Kaiqi Fan, Zhimin Lin, et al.
Dermatitis (2025)
Closed Access
Page 1 - Next Page

Scroll to top